Foreign Generics See Ripe Market In Price Conscious Japan
This article was originally published in PharmAsia News
Executive Summary
Generic makers in other countries are setting their sights on Japan as the place for major expansions. Israel's Teva Pharmaceutical Industries and India's Ranbaxy Laboratories are among companies that plan to take advantage of the Japanese government's initiative to reduce the price of prescriptions. Ranbaxy has been trying to gain ground in Japan's market since it teamed with Nippon Chemiphar six years ago, but now it hopes to gain ground with its amlodipine generic of Pfizer's blockbuster Norvasc blood pressure drug. Other foreign generics planning expansions include Sandoz of Germany and Zydus Cadila of India. (Click here for more - a subscription may be required
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.